Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
- 15 May 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (10), 1912-1921
- https://doi.org/10.1200/jco.2003.05.073
Abstract
Purpose: Fibroblast growth factor receptor 3 (FGFR3) mutations were recently found at a high frequency in well-differentiated urothelial cell carcinoma (UCC). We investigated the relationship between FGFR3 status and three molecular markers (MIB-1, P53, and P27kip1) associated with worse prognosis and determined the reproducibility of pathologic grade and molecular variables. Patients and Methods: In this multicenter study, we included 286 patients with primary (first diagnosis) UCC. The histologic slides were reviewed. FGFR3 status was examined by polymerase chain reaction–single strand conformation polymorphism and sequencing. Expression levels of MIB-1, P53, and P27kip1 were determined by immunohistochemistry. Mean follow-up was 5.5 years (range, 0.4 to 18.4 years). Results: FGFR3 mutations were detected in 172 (60%) of 286 UCCs. Grade 1 tumors had an FGFR3 mutation in 88% of patient samples and grade 3 tumors in 16% of patient samples. Conversely, aberrant expression patterns of MIB-1, P53, and P27kip1 were seen in 5%, 2%, and 3% of grade 1 tumors and in 85%, 60%, and 56% of grade 3 tumors, respectively. In multivariate analysis with recurrence rate, progression, and disease-specific survival as end points, the combination of FGFR3 and MIB-1 proved independently significant in all three cases. By using these two molecular markers, three molecular grades (mGs) could be identified: mG1 (mutation; normal expression), favorable prognosis; mG2 (two remaining combinations), intermediate prognosis; and mG3 (no mutation; high expression), poor prognosis. The molecular variables were more reproducible than pathologic grade (85% to 100% v 47% to 61%). Conclusion: The FGFR3 mutation represents the favorable molecular pathway of UCC. Molecular grading provides a new, simple, and highly reproducible tool for clinical decision making in UCC patients.Keywords
This publication has 35 references indexed in Scilit:
- Methods for Genotyping Single Nucleotide PolymorphismsAnnual Review of Genomics and Human Genetics, 2001
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Distinct Missense Mutations of the FGFR3 Lys650 Codon Modulate Receptor Kinase Activation and the Severity of the Skeletal Dysplasia PhenotypeAmerican Journal of Human Genetics, 2000
- MIB-1 as a proliferative marker in transitional cell carcinoma of the bladderCancer, 2000
- p53 Immunohistochemistry as a Prognostic Marker in Bladder CancerEuropean Urology, 2000
- Loss of p27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancersEuropean Journal Of Cancer, 1999
- The genetics of transitional cell carcinoma: progress and potential clinical applicationBJU International, 1999
- The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic indexBritish Journal of Urology, 1998
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal Of Cancer, 1995